TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Ontology highlight
ABSTRACT: This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
DISEASE(S): Gastrointestinal Stromal Tumor (gist),Colorectal Cancer,Gastric Cancer,Esophageal Cancer,Pancreatic Cancer,Rectal Cancer,Gastrointestinal Stromal Tumors
PROVIDER: 2200015 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA